Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioArctic AB Class B ( ($SE:BIOA.B) ) has shared an update.
BioArctic AB has announced the first treatment of a patient with Leqembi in Finland, marking a significant milestone in its efforts to address early Alzheimer’s disease in the Nordics. The approval and implementation of Leqembi, which targets amyloid-beta protofibrils and amyloid plaque, represent a strategic advancement for BioArctic as it seeks to expand its impact in the pharmaceutical industry and provide new treatment options for Alzheimer’s patients.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a pharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, with a particular emphasis on Alzheimer’s disease. The company collaborates with Eisai to promote Leqembi, a treatment targeting the underlying causes of Alzheimer’s, in the Nordic region.
Average Trading Volume: 328,346
Technical Sentiment Signal: Buy
Current Market Cap: SEK25.79B
Find detailed analytics on BIOA.B stock on TipRanks’ Stock Analysis page.